US Stock Insider Trading | Rhythm disclosed 9 insider transactions on February 19

2026-02-24 07:04:20

On February 19, 2026, Rhythm (RYTM) disclosed nine insider transactions. Executive Smith Hunter C sold 1,692 shares on that day.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 19, 2026	Executive	Smith Hunter C	February 17, 2026	Sell	900	101.70	$91,500
February 19, 2026	Executive	Smith Hunter C	February 19, 2026	Sell	585	103.28	$60,400
February 19, 2026	Executive	Smith Hunter C	February 17, 2026	Sell	200	100.52	$20,100
February 19, 2026	Executive	Smith Hunter C	February 19, 2026	Sell	1,692	100.92	$1,708,200
February 19, 2026	Executive	Smith Hunter C	February 19, 2026	Sell	800	102.10	$81,680
February 19, 2026	Executive	Smith Hunter C	February 17, 2026	Sell	1,069	103.00	$110,000
February 19, 2026	Executive	Smith Hunter C	February 17, 2026	Sell	1,200	99.42	$119,300
February 19, 2026	Executive	Smith Hunter C	February 19, 2026	Sell	1,308	100.27	$131,200
February 19, 2026	Executive	Smith Hunter C	February 17, 2026	Sell	200	103.84	$20,800
February 12, 2026	Executive	Smith Hunter C	February 11, 2026	Sell	2,266	98.37	$222,900

[Company Profile]

Rhythm Pharmaceuticals, Inc. is a Delaware-based company founded in February 2013. It is a global, commercial-stage biopharmaceutical company dedicated to changing the lives of patients and their families affected by rare neuroendocrine diseases. The company focuses on advancing melanocortin-4 receptor (MC4R) agonists, including their flagship asset IMCIVREE, as targeted therapies designed to treat hyperphagia and severe obesity caused by rare MC4R pathway disorders.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes